Becampanel
Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM). It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Becampanel
Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM). It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.
has abstract
Becampanel (INN) (code name AM ...... ver completed clinical trials.
@en
CAS number
188696-80-2
FDA UNII code
X3D0O800AJ
PubChem
Wikipage page ID
44,908,849
page length (characters) of wiki page
Wikipage revision ID
977,255,434
Link from a Wikipage to another Wikipage
ATC prefix
None
@en
CAS number
ChemSpiderID
IUPAC name
phosphonic acid
@en
PubChem
SMILES
c1c[N+][O-]
@en
StdInChIKey
ABFMMCZFKUIJGQ-UHFFFAOYSA-N
@en
UNII
X3D0O800AJ
@en
wikiPageUsesTemplate
hypernym
comment
Becampanel (INN) (code name AM ...... ver completed clinical trials.
@en
label
Becampanel
@en